Publication | Closed Access

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

Versus DabrafenibVal600 Braf-mutant MelanomaOncologyMelanomaPharmacotherapyDermatologyCancer TreatmentMedicineMolecular OncologyPhase 3